| Literature DB >> 12509966 |
Marilena Vered1, Izhar Shohat, Amos Buchner.
Abstract
UNLABELLED: Ameloblastoma is a locally aggressive tumor with possible lethal potential. Currently extensive surgery is the most acceptable treatment modality. AIM: To investigate the presence of EGFR in ameloblastoma in order to consider using newly developed anti-EGFR therapeutic agents in cases of unresectable tumors. The study consisted of 58 formalin-fixed, paraffin-embedded specimens of ameloblastoma that were immunohistochemically stained with a monoclonal anti-EGFR antibody (clone 31G7). Positive and negative controls determined specificity of the antibody. A staining score based on the staining intensity and the proportion of stained cells was established, ranging between 0 and 2. All specimens were EGFR positive; 8 (14%) exhibited the maximum score of 2 and 19 (33%) scored between 1 and 2. Since ameloblastomas are EGFR-positive tumors, anti-EGFR agents could be considered to reduce the size of large tumors and to treat unresectable tumors that are in close proximity to vital structures. Copyright 2002 Elsevier Science Ltd.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12509966 DOI: 10.1016/s1368-8375(02)00034-9
Source DB: PubMed Journal: Oral Oncol ISSN: 1368-8375 Impact factor: 5.337